阿克拉霉素A治疗恶性淋巴瘤23例临床研究

CLINICAL STUDY OF ACLARUBICIN FOR TREATMENT OF MALIGNANT LYMPHOMA-A REPORT OF 23 CASES

阿克拉霉素A(ACR)是一种新的蒽环类抗肿瘤抗生素,动物模型研究表明其心脏毒性较低。我们对23例经病理确诊的恶性淋巴瘤患者进行了前瞻性研究,其中20例可评价疗效,23例均町评价毒性反应。我们采用了两种剂量方案:ACR12.5mg/m^2/日×5天;25mg/m^2/日×3天。结果表明:本组总有效率为55％(11/20),其中3例(15％)获CR,8例(40％)为PR。胃肠道毒性常见但不严重。血液学毒性为剂量限制性毒性,表现为轻到中度的骨髓抑制。腹泻、口腔炎及静脉炎少见,无脱发及充血性心衰。全组有4例出现不伴临床症状的ECG改变,发生率为17.4％。对于ACR治疗淋巴瘤的合适剂量方案及远期作用尚需进一步研究。

Aclarubicin (ACR) is a new anthracy cloine antibiotic with a reduced cardiac toxicity in animal models. A prospective study was performend in a total of 23 patients with malignant lymphoma (ML), 20 of whom were evaluable for response. Two dose schedules were designed : 12.5mg/M2 was administered daily by intravenous injection for 5 days, and 25mg/M2 for 3 days. The overall response rate was 55% (11/20), among them 3 cases (15% ) with CR and 8 cases (40% ) with PR were found after 3 cycles of treatment. The gastrointestinal toxivity occured frequently but not severely Hematologic to xicity was dose limiting and a mild to moderate grade myelosuppression was noted. There was no alopecia and congestive heart failure. Diarrhea, stomatitis and phebitis were uncommon. ECG changes were observed in 4 out of 23 patients (17.4%) and were not associated with clinical symptoms. Further studies are needed for optimal dose schedule and remote effect of ACR in the treatment of ML.